Combinations of T cell checkpoint inhibitors with inhibitors of E-selectin or inhibitors of CXCR4 or with heterobifunctional inhibitors of both E-selectin and CXCR4
Heterobifunctional inhibition comprising a T cell checkpoint inhibitor comprising an E-selectin inhibitor, a CXCR4 receptor inhibitor, and / or at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor Disclosed are compositions and methods for the treatment of diseases, disorders, and / or conditions associated with increased regulatory T lymphocyte cell (Treg cell) function, comprising administering in combination with an agent. In one aspect, the disease, disorder, or condition is selected from a bacterial infection, a viral infection, a condition associated with at least one bacterial infection, and a condition associated with at least one viral infection.Ｔ細胞チェックポイント阻害剤を、Ｅ－セレクチン阻害剤、ＣＸＣＲ４受容体阻害剤、および／または少なくとも１つのＣＸＣＲ４受容体阻害剤に連結された少なくとも１つのＥ－セレクチン阻害剤を含むヘテロ二機能性阻害剤と組み合わせて投与することを含む、増加した制御性Ｔリンパ球細胞（Ｔｒｅｇ細胞）機能に関連した疾患、障害、および／または状態の処置のための組成物および方法が開示される。一局面では、上記疾患、障害、または状態は、細菌感染症、ウイルス感染症、少なくとも１つの細菌感染に関係する状態、および少なくとも１つのウイルス感染に関係する状態から選択される。
